Streetbeat News

ALLR

Allarity Therapeutics, Inc.

https://www.allarity.com

Industry

Biotechnology

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Open

1.41

Mkt cap

1.9M

Volume

180K

High

1.41

P/E Ratio

-0.12

52-wk high

666.00

Low

1.33

Div yield

N/A

52-wk low

1.26

Health care stocks experienced significant movement in Wednesday's intraday session. Sera Prognostics (SERA) saw a massive increase of 231.9%, while OptiNose (OPTN) led the decliners with a 22.4% drop. Other notable gainers include Phio Pharma (PHIO), Syros Pharmaceuticals (SYRS), Altimmune (ALT), Arvinas (ARVN), and Altamira Therapeutics (CYTO). On the losing side were Mira Pharmaceuticals (MIRA), InVivo Therapeutics Hldg (NVIV), Allarity Therapeutics (ALLR), GlucoTrack (GCTK), and Sonoma Pharmaceuticals (SNOA).

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 5:31 pm

SentinelOne, Inc. (NYSE:S) shares surged over 18% in pre-market trading following the release of their Q3 results, which exceeded analyst expectations. The company reported $164.2 million in revenue, surpassing the $156.09 million estimate, and an adjusted loss of 3 cents per share, better than the expected 8 cents per share loss. SentinelOne also increased its full-year 2024 revenue forecast from $605 million to $616 million.

Portfolio Pulse from Lisa Levin

December 06, 2023 | 1:32 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant movements. Phio Pharma (PHIO) led the gainers with a 33.9% increase, while OptiNose (OPTN) saw the largest decline among the losers, dropping 16.3%. The changes in stock prices are reflective of market reactions to company-specific news or broader sector shifts.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 1:06 pm

In Tuesday's after-market session, several healthcare stocks experienced significant movements. Phio Pharma (PHIO) saw a 19.6% increase, while Lucy Scientific Discovery (LSDI) rose by 9.34%. Aclaris Therapeutics (ACRS) went up by 8.47%, and Minerva Surgical (UTRS) by 8.36%. Pasithea Therapeutics (KTTA) and Phreesia (PHR) also saw gains of 6.77% and 5.76%, respectively. On the downside, Allarity Therapeutics (ALLR) dropped by 8.1%, InVivo Therapeutics (NVIV) by 7.06%, Longeveron (LGVN) by 6.2%, Surrozen (SRZN) by 6.01%, Impel Pharmaceuticals (IMPL) by 5.58%, and BioCardia (BCDA) by 5.49%.

Portfolio Pulse from Benzinga Insights

December 05, 2023 | 9:31 pm

Daktronics, Inc. (NASDAQ:DAKT) shares fell over 10% due to weaker-than-expected quarterly results, with earnings of 5 cents per share versus the estimated 13 cents and sales of $199.37 million against the expected $213.70 million. Other stocks experienced significant movements in Tuesday's mid-day session, with notable gainers including Meiwu Technology Company Limited (WNW), Volato Group, Inc. (SOAR), and Clearmind Medicine Inc. (CMND), among others. Losers included Replimune Group, Inc. (REPL), iBio, Inc. (IBIO), and Designer Brands Inc. (DBI), which all saw substantial declines in their share prices.

Portfolio Pulse from Lisa Levin

December 05, 2023 | 6:06 pm

U.S. stocks were mixed with the Dow Jones falling 100 points and the NASDAQ rising. Consumer discretionary shares were up, while materials shares dipped. The ISM services PMI increased to 52.7 in November, exceeding estimates. Clearmind Medicine, Allarity Therapeutics, and Mercurity Fintech Holding saw stock price increases due to positive company news. Conversely, Replimune Group, iBio, and Designer Brands experienced significant stock price drops following negative announcements. Oil and gold prices were up, while silver and copper declined. European shares were mostly higher, and Asian markets closed mostly lower. U.S. job openings decreased, and the Economic Optimism Index fell.

Portfolio Pulse from Lisa Levin

December 05, 2023 | 5:11 pm

U.S. stocks traded lower with the Nasdaq Composite down over 50 points. J.M. Smucker Company (NYSE:SJM) reported Q2 earnings with sales of $1.94 billion, missing estimates but beating EPS expectations and revising FY24 EPS guidance. Volato Group, Inc. (NYSE:SOAR), Allarity Therapeutics, Inc. (NASDAQ:ALLR), and Meiwu Technology Company Limited (NASDAQ:WNW) saw their shares rise significantly. Conversely, Replimune Group, Inc. (NASDAQ:REPL), iBio, Inc. (NYSE:IBIO), and Designer Brands Inc. (NYSE:DBI) experienced sharp declines in their share prices.

Portfolio Pulse from Lisa Levin

December 05, 2023 | 2:39 pm

Allarity Therapeutics' stock (ALLR) is trading higher following the announcement of positive initial results from its Phase 2 clinical trial for stenoparib in advanced ovarian cancer.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 2:21 pm

In Monday's after-market session, several healthcare stocks experienced significant movements. NGM Biopharmaceuticals (NGM) saw an 11.5% increase, while TC BioPharm (TCBP) rose by 11.24%. Nemaura Medical (NMRD), Exagen (XGN), NanoVibronix (NAOV), and Allarity Therapeutics (ALLR) also posted gains. Conversely, Alzamend Neuro (ALZN) dropped by 19.4%, Gain Therapeutics (GANX) fell by 16.37%, Acutus Medical (AFIB) declined by 16.04%, AVITA Medical (RCEL) decreased by 11.2%, Vicarious Surgical (RBOT) went down by 10.67%, and Forte Biosciences (FBRX) fell by 9.77%.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 9:31 pm

During Friday's after-market session, several health care stocks experienced significant movement. Coherus BioSciences (CHRS), Aligos Therapeutics (ALGS), ContraFect (CFRX), ProKidney (PROK), Virpax Pharmaceuticals (VRPX), and Reviva Pharmaceuticals (RVPH) saw their shares rise, with Coherus BioSciences leading the gainers with an 11.7% increase. On the other hand, Connect Biopharma Hldgs (CNTB), SeaStar Medical Holding (ICU), Allarity Therapeutics (ALLR), Lipella Pharmaceuticals (LIPO), Sight Sciences (SGHT), and MSP Recovery (LIFW) experienced a decline in their stock prices, with Connect Biopharma Hldgs leading the losers with a 10.0% decrease.

Portfolio Pulse from Benzinga Insights

October 27, 2023 | 9:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.